Genor Biopharma Holdings Limited (FRA:67N0)

Market Cap	195.64M
Revenue (ttm)	26.63M
Net Income (ttm)	3.44M
Shares Out	n/a
EPS (ttm)	0.01
PE Ratio	56.92
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	263
Open	0.3580
Previous Close	0.3540
Day's Range	0.3580 - 0.3580
52-Week Range	0.1850 - 0.5700
Beta	n/a
RSI	46.48
Earnings Date	Nov 28, 2025

About Genor Biopharma Holdings

Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company’s principal drug candidates include GB242, an infliximab (Remicade) biosimilar for rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, and Crohn’s disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for breast cancer; and GB492, a stimulator of interferon genes combined with GB226, currently under Phase 1/2 clinical trial to treat solid t...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 24
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 67N0

Financial Performance

Financial numbers in CNY